Catalent

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Avangrid, Inc. By Iberdrola, S.A.

Retrieved on: 
星期二, 五月 28, 2024
Catalent, Person, Telephone, AGR, Acquisition, LLP, Holding company

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Avangrid, Inc. by Iberdrola, S.A. (“IBDRY”).

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Avangrid, Inc. by Iberdrola, S.A. (“IBDRY”).
  • As a result of the merger, Catalent stockholders will receive $35.75 per share in cash.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

Tim Scott to Succeed Joe Panetta as Biocom California President and CEO

Retrieved on: 
星期二, 五月 28, 2024
Medical Devices, Health, Research, Pharmaceutical, Science, Biotechnology, Patient, UC, Organization, STEM, Biochemistry, Entrepreneurship, Education, Workforce, University, Therapy, Ecosystem, Incubator, Growth, Human, JD, Drug discovery, Catalent, Pharma, Glycogen storage disease, Multimedia, CDMO, Management

Biocom California, the association representing the California life science industry, today announced that it has named Tim Scott as its president and CEO, effective January 1, 2025.

Key Points: 
  • Biocom California, the association representing the California life science industry, today announced that it has named Tim Scott as its president and CEO, effective January 1, 2025.
  • Mr. Scott will succeed Joe Panetta, Biocom California’s current president and CEO, who has led the organization for 25 years.
  • Chair-elect Sabrina Martucci Johnson, president and CEO of Daré Bioscience, will succeed Mr. Scott as board chair.
  • View the full release here: https://www.businesswire.com/news/home/20240528207819/en/
    Tim Scott, Chairman, Biocom California Board of Directors (Photo: Business Wire)
    Mr. Panetta, who joined Biocom in 1999, has been instrumental in spearheading initiatives that have significantly advanced the biopharma and medical device landscape in California.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Avangrid, Inc. By Iberdrola, S.A.

Retrieved on: 
星期五, 五月 17, 2024
Catalent, Person, Telephone, AGR, Acquisition, LLP, Holding company

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Avangrid, Inc. by Iberdrola, S.A. (“IBDRY”).

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Avangrid, Inc. by Iberdrola, S.A. (“IBDRY”).
  • As a result of the merger, Catalent stockholders will receive $35.75 per share in cash.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Retrieved on: 
星期三, 五月 8, 2024
FDA, Biopharmaceutical, Partnership, AAV, CDMO, Catalent, Universal, Patient, Siren, SAN, CGMP, Pharmaceutical industry

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.

Key Points: 
  • SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
  • Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials.
  • “We look forward to working with Catalent, a leading CDMO with premier capabilities in AAV vector development and manufacturing, on the development of our AAV Immuno-Gene Therapies,” said Dr. Nicole Paulk, CEO, Founder, and President of Siren Biotechnology.
  • We are excited to work together to pioneer a pathway for the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to patients with cancer.”

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, HRT, CTLT

Retrieved on: 
星期六, 五月 4, 2024
Sale, HireRight, Catalent, Advertising, General Atlantic, Fraud, Security (finance)

If you are a Codorus shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Codorus shareholder, click here to learn more about your rights and options .
  • HireRight Holdings Corporation (NYSE: HRT)’s sale to affiliates of General Atlantic, L.P. and Stone Point Capital LLC for $14.35 per share in cash.
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期五, 五月 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期五, 五月 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCP, NXPL, CTLT

Retrieved on: 
星期五, 四月 26, 2024
Sale, Catalent, Advertising, Fraud, Security (finance)

If you are a NextPlat shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a NextPlat shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, CHRD

Retrieved on: 
星期六, 四月 20, 2024
Enerplus, Sale, HireRight, Advertising, Catalent, General Atlantic, Fraud, Security (finance)

HireRight Holdings Corporation (NYSE: HRT)’s sale to affiliates of General Atlantic, L.P. and Stone Point Capital LLC for $14.35 per share in cash.

Key Points: 
  • HireRight Holdings Corporation (NYSE: HRT)’s sale to affiliates of General Atlantic, L.P. and Stone Point Capital LLC for $14.35 per share in cash.
  • If you are a HireRight shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

Retrieved on: 
星期四, 四月 11, 2024
Steps, CTLT, Catalent, Novo Nordisk Foundation, Acquisition, News, SAN

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE: CTLT) by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation.

Key Points: 
  • SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE: CTLT) by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation.
  • Under the terms of the agreement, Catalent stockholders will receive $63.50 in cash for each share of Catalent common stock owned.
  • On February 2, 2024, the companies announced a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion.
  • Robbins LLP is concerned that Catalent's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.